Literature DB >> 32634335

Reply to L.H. Einhorn et al.

Deaglan McHugh1, George J Bosl1, Samuel A Funt1, Darren R Feldman1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32634335      PMCID： PMC7479756          DOI： 10.1200/JCO.20.01339

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Adjuvant Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors: Is This the Preferred Option?

Authors:  Lawrence H Einhorn; Nabil Adra; Nasser Hanna; Craig Nichols
Journal:  J Clin Oncol       Date:  2020-07-07       Impact factor: 44.544

2.  Fear of cancer recurrence in adolescent and young adult cancer survivors: A systematic review of the literature.

Authors:  Yuan Yang; Wen Li; Yunhong Wen; Hongmei Wang; Hengwen Sun; Weijiang Liang; Bin Zhang; Gerry Humphris
Journal:  Psychooncology       Date:  2019-02-17       Impact factor: 3.894

3.  Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer.

Authors:  S D Williams; D M Stablein; L H Einhorn; F M Muggia; R B Weiss; J P Donohue; D F Paulson; K W Brunner; E M Jacobs; J T Spaulding
Journal:  N Engl J Med       Date:  1987-12-03       Impact factor: 91.245

4.  Acute myelogenous leukemia after treatment for malignant germ cell tumors in children.

Authors:  D T Schneider; E Hilgenfeld; D Schwabe; W Behnisch; A Zoubek; R Wessalowski; U Göbel
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

5.  Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.

Authors:  Deaglan J McHugh; Samuel A Funt; Deborah Silber; Andrea Knezevic; Sujata Patil; Devon O'Donnell; Stephanie Tsai; Victor E Reuter; Joel Sheinfeld; Brett S Carver; Robert J Motzer; Dean F Bajorin; George J Bosl; Darren R Feldman
Journal:  J Clin Oncol       Date:  2020-02-28       Impact factor: 44.544

6.  Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer.

Authors:  Mette Sprauten; Thomas H Darrah; Derick R Peterson; M Ellen Campbell; Robyn E Hannigan; Milada Cvancarova; Clair Beard; Hege S Haugnes; Sophie D Fosså; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

7.  Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy.

Authors:  Marianne Brydøy; Sophie D Fosså; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Olav Dahl
Journal:  Eur Urol       Date:  2010-04-02       Impact factor: 20.096

8.  Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.

Authors:  D Scott Ernst; Penny Brasher; Peter M Venner; Piotr Czaykowski; Malcolm J Moore; Leonard Reyno; Eric Winquist; Roanne Segal; Desiree Hao
Journal:  Can J Urol       Date:  2005-04       Impact factor: 1.344

9.  Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.

Authors:  R L Schilsky; T Anderson
Journal:  Ann Intern Med       Date:  1979-06       Impact factor: 25.391

10.  Quality of surveillance for stage I testis cancer in the community.

Authors:  Hua-yin Yu; Rodger A Madison; Claude M Setodji; Christopher S Saigal
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.